CSI Market
Sign In | Register

Vertex Pharmaceuticals Inc (VRTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access VRTX quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Vertex Pharmaceuticals Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income3,953.20
Depreciation & amortization209.80
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)379.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-524.20
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation685.90
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Derivative Gain Loss On Derivative Net-
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost-
Impairment of Intangible Assets Indefinitelived Excluding Goodwill Including Effect of Discontinued Operations-
Equity Securities Fv Ni Unrealized Gain Loss-
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Gain (Loss) on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable-347.30
Increase (Decrease) in Accounts Payable36.80
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-116.90
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-396.00
Other Working Capital-362.30
Other Noncash Income (Expense)113.40
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities3,631.40
Investing Activities
Capital Expenditures-437.60
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities5,897.40
Payments to Acquire Available-for-sale Securities, Debt-6,396.50
Real Estate Investments0.00
Paymentto Acquire Preferred Stock-
Proceeds from Return Relatedto Financing Lease Obligation-
Payment To Acquire Preferred Stock And Notes Receivable-
Payments To Acquire Equity Securities Fv Ni-
Payments To Acquire Debt Securities Available For Sale Asset Acquisition-
Proceeds From Payments For Finite Lived Intangible Assets-
Proceeds From Sale Of Equity Securities Fv Ni16.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities-24.70
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-945.40
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-1,889.70
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-4,938.40
Proceeds From Issuance Of Secured Debt And Sale Of Future Milestone Payments-
Repayments Of Facility Lease Obligations-
Paymentson Construction Financing Lease Obligations-
Proceeds From Collaborative Funding-
Repayments of Collaborative Funding-
Paymentson Capital Lease and Construction Financing Lease Obligations-
Finance Lease Principal Payments-5.40
Proceeds On Construction Capital Lease Obligations-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents4,572.20
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-2,261.30
Effect of exchange rate on cash flow90.90
Discontinued operations0.00
Free Cash Flow3,193.80
Total Cash Flow515.60
4 historic quarters locked

Sign in to unlock the full Vertex Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Vertex Pharmaceuticals Inc Ma Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 13, 2026
  • Source: vrtx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000875320-26-000056

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License